Updated Pediatric Venous Thromboembolism Treatment Guidelines Now Available

The American Society of Hematology and ISTH have published updated guidelines for managing pediatric venous thromboembolism, emphasizing new anticoagulant options and improved care strategies.
The American Society of Hematology (ASH) in collaboration with the International Society on Thrombosis and Hemostasis (ISTH) has released comprehensive updated clinical guidelines for treating venous thromboembolism (VTE) in children. Published in the journal Blood Advances, these guidelines are the result of a meticulous review process by an expert panel aiming to enhance clinical care through evidence-based recommendations.
This update marks the first revision since 2018, incorporating the latest research findings into 16 revised recommendations and four new ones. A significant change in these guidelines is the recommendation to consider direct oral anticoagulants—specifically dabigatran and rivaroxaban—instead of traditional therapies such as low molecular weight heparin and vitamin K antagonists. This shift is guided by emerging evidence supporting the safety and efficacy of these newer medications in pediatric populations.
Dr. Belinda R. Avalos, ASH president, emphasized that these guidelines serve as a vital resource for clinicians, providing updated, high-quality information to improve patient outcomes. Pantep Angchaisuksiri, MD, presiding over ISTH, highlighted the importance of collaboration in advancing pediatric VTE management and commitment to ongoing research.
Though rare at a population level, VTE in children often occurs in hospitalized children and can be life-threatening. It manifests mainly as deep vein thrombosis (DVT)—a clot in deep veins—or pulmonary embolism (PE), which involves a clot blocking an artery in the lungs. Complex illnesses in children increase the risk, and proper management is crucial for long-term health.
As pediatric thrombosis cases rise among children with complex health issues, healthcare providers and parents are encouraged to stay informed about the latest treatment options. Dr. Paul Monagle, a pediatric hematologist and chair of the guidelines panel, emphasized that well-managed care can significantly influence long-term outcomes in children affected by VTE.
For more detailed information, the guidelines are published in Blood Advances (2025), and can be accessed via the DOI: doi.org/10.1182/bloodadvances.2024015328.
Source: https://medicalxpress.com/news/2025-05-clinical-guidelines-pediatric-venous-thromboembolism.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Fecal Microbiota Transplantation Emerging as a First-Line Treatment for C. difficile Infection
Recent studies suggest fecal microbiota transplantation (FMT) may become a first-line treatment for Clostridioides difficile infections, offering a potentially more effective alternative to traditional antibiotics.
Identifying Behavioral Signs of Childhood Maltreatment
A recent study highlights how non-invasive behavioral assessments can effectively identify children affected by maltreatment, enabling earlier intervention and targeted support. Discover the new approaches revolutionizing childhood trauma detection.
Research Uncovers How Protein and Immune Patterns Influence Personalized Melanoma Treatments
New research reveals how protein levels and immune cell patterns in melanoma can guide personalized treatment strategies, advancing precision oncology.